{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-040664","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.106331+00:00","generated_at":"2026-05-16T23:46:39.848821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M","bullets":["KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.","Net loss $(0.2)M vs profit $8.7M in Q3 2024; diluted EPS $(0.00) vs $0.17.","IDMC recommended 160 mcg dose for brenetafusp in Phase 3 PRISM-MEL-301; on track to complete enrollment in 1H 2026.","Cash, equivalents & marketable securities $892.4M as of Sept 30, 2025; expects $65M rebate payments in Q4.","Phase 3 TEBE-AM (tebentafusp) enrollment on track for 1H 2026 completion; multiple pipeline programs advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-040664","json":"https://secwatch.observer/filing/0001140361-25-040664.json","markdown":"https://secwatch.observer/filing/0001140361-25-040664.md","text":"https://secwatch.observer/filing/0001140361-25-040664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/0001140361-25-040664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/ef20058378_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:46:39.848821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}